Literature DB >> 15756594

Expression of ADAM15 in lung carcinomas.

A Schütz1, W Härtig, M Wobus, J Grosche, Ch Wittekind, G Aust.   

Abstract

ADAM15, a member of the ADAM (a disintegrin and metalloprotease) family, is a membrane protein containing both protease and adhesion domains and may, thus, be involved in tumor invasion and metastasis. The aim of this study was to analyze the expression of ADAM15 and its potential ligand, integrin alpha(v)beta3 (CD51/CD61), in lung carcinoma cell lines and tissues. Most small cell lung carcinomas (SCLCs) and non-SCLC cell lines were ADAM15, alpha(v) and beta3 integrin mRNA positive. Half of the cell lines expressed ADAM15, and three expressed the alpha(v)beta3 heterodimer at the cell surface as shown using flow cytometry. Paraffin sections of pulmonary epithelial tumors, including SCLCs (n=26), squamous cell cancer (SCCs, n=27) and adenocarcinomas (ACs, n=17) were stained with antibodies to the ectosolic and cytosolic domain of ADAM15 and alpha(v)beta3 integrin complex. The results were scored (0-12, according to Remmele's score). Normal epithelial cells of the lung were negative or slightly positive for ADAM15 (score<2). The score was always significantly higher for tumor cells. ACs showed the strongest staining (tumor center; ADAM15ecto; mean+/-SEM; 5.47+/-1.04), whereas SCLCs only showed weak ADAM15 expression (2.67+/-0.42; SCCs: 3.62+/-0.62). Frequently, significantly stronger ADAM15 expression has been shown in tumor cells located at the front of invasion compared with those within solid formations. Overall analysis of all tumor specimens and each tumor type revealed no significant correlation between tumor stage or degree of differentiation and ADAM15 ectosolic or cytosolic domain expression in tumor cells. Both molecules are often co-localized in the same tumor cells in ADAM15- and alpha(v)beta3 integrin-positive carcinomas. In summary, lung carcinoma cell lines and tissues were frequently ADAM15 positive.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15756594     DOI: 10.1007/s00428-004-1193-z

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  49 in total

Review 1.  ADAMs: modulators of cell-cell and cell-matrix interactions.

Authors:  Judith M White
Journal:  Curr Opin Cell Biol       Date:  2003-10       Impact factor: 8.382

2.  The role of ADAM 15 in glomerular mesangial cell migration.

Authors:  John Martin; Lisa V Eynstone; Malcolm Davies; John D Williams; Robert Steadman
Journal:  J Biol Chem       Date:  2002-06-28       Impact factor: 5.157

3.  Expression of members of the novel membrane linked metalloproteinase family ADAM in cells derived from a range of haematological malignancies.

Authors:  E Wu; P I Croucher; N McKie
Journal:  Biochem Biophys Res Commun       Date:  1997-06-18       Impact factor: 3.575

4.  Expression and localization of alpha v integrins and their ligand vitronectin in normal ovarian epithelium and in ovarian carcinoma.

Authors:  F Carreiras; Y Denoux; C Staedel; M Lehmann; F Sichel; P Gauduchon
Journal:  Gynecol Oncol       Date:  1996-08       Impact factor: 5.482

5.  Characterization of the state of differentiation of six newly established human non-small-cell lung cancer cell lines.

Authors:  G Bepler; A Koehler; P Kiefer; K Havemann; K Beisenherz; G Jaques; C Gropp; M Haeder
Journal:  Differentiation       Date:  1988       Impact factor: 3.880

6.  beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer.

Authors:  T Brabletz; A Jung; S Dag; F Hlubek; T Kirchner
Journal:  Am J Pathol       Date:  1999-10       Impact factor: 4.307

7.  Alpha(v)beta(3) integrin engagement enhances cell invasiveness in human multiple myeloma.

Authors:  Roberto Ria; Angelo Vacca; Domenico Ribatti; Francesco Di Raimondo; Francesca Merchionne; Franco Dammacco
Journal:  Haematologica       Date:  2002-08       Impact factor: 9.941

8.  Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front.

Authors:  T Brabletz; A Jung; K Hermann; K Günther; W Hohenberger; T Kirchner
Journal:  Pathol Res Pract       Date:  1998       Impact factor: 3.250

9.  Evidence of antiangiogenic and antimetastatic activities of the recombinant disintegrin domain of metargidin.

Authors:  Véronique Trochon-Joseph; Dominique Martel-Renoir; Lluis M Mir; Annick Thomaïdis; Paule Opolon; Elisabeth Connault; Hong Li; Christophe Grenet; Françoise Fauvel-Lafève; Jeannette Soria; Chantal Legrand; Claudine Soria; Michel Perricaudet; He Lu
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

10.  Interaction of metargidin (ADAM-15) with alphavbeta3 and alpha5beta1 integrins on different haemopoietic cells.

Authors:  D Nath; P M Slocombe; P E Stephens; A Warn; G R Hutchinson; K M Yamada; A J Docherty; G Murphy
Journal:  J Cell Sci       Date:  1999-02       Impact factor: 5.285

View more
  12 in total

1.  ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease.

Authors:  Rainer Kuefer; Kathleen C Day; Celina G Kleer; Michael S Sabel; Matthias D Hofer; Sooryanarayana Varambally; Christoph S Zorn; Arul M Chinnaiyan; Mark A Rubin; Mark L Day
Journal:  Neoplasia       Date:  2006-04       Impact factor: 5.715

2.  The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation.

Authors:  Abdo J Najy; Kathleen C Day; Mark L Day
Journal:  J Biol Chem       Date:  2008-04-22       Impact factor: 5.157

3.  Baseline and decline of serum ADAM28 during chemotherapy of advanced non-small cell lung cancer: a probable predictive and prognostic factor.

Authors:  Yan-ling Lv; Dong-mei Yuan; Qing-bo Wang; Ping Zhan; Liang Luo; Tang-feng Lv; Hong-bing Liu; Yu-feng Li; Jian Wen; Yong Song
Journal:  Med Oncol       Date:  2012-02-22       Impact factor: 3.064

4.  Overexpression of ADAMTS5 can regulate the migration and invasion of non-small cell lung cancer.

Authors:  Jun Gu; Jie Chen; Jian Feng; Yifei Liu; Qun Xue; Guoxin Mao; Ling Gai; Xiaoning Lu; Rui Zhang; Jialin Cheng; Yanxia Hu; Mengting Shao; Hong Shen; Jianan Huang
Journal:  Tumour Biol       Date:  2016-01-06

5.  Lung Adenocarcinomas and Lung Cancer Cell Lines Show Association of MMP-1 Expression With STAT3 Activation.

Authors:  Alexander Schütz; Katrin Röser; Jana Klitzsch; Franziska Lieder; Fritz Aberger; Wolfgang Gruber; Kristina M Mueller; Alexander Pupyshev; Richard Moriggl; Karlheinz Friedrich
Journal:  Transl Oncol       Date:  2015-04       Impact factor: 4.243

6.  Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers.

Authors:  Christoph Burdelski; Michael Fitzner; Claudia Hube-Magg; Martina Kluth; Asmus Heumann; Ronald Simon; Till Krech; Till Clauditz; Franziska Büscheck; Stefan Steurer; Corinna Wittmer; Andrea Hinsch; Andreas M Luebke; Frank Jacobsen; Sarah Minner; Maria Christina Tsourlakis; Burkhard Beyer; Thomas Steuber; Imke Thederan; Guido Sauter; Jakob Izbicki; Thorsten Schlomm; Waldemar Wilczak
Journal:  Neoplasia       Date:  2017-03-08       Impact factor: 5.715

7.  Helping Eve overcome ADAM: G-quadruplexes in the ADAM-15 promoter as new molecular targets for breast cancer therapeutics.

Authors:  Robert V Brown; Vanessa C Gaerig; Taesha Simmons; Tracy A Brooks
Journal:  Molecules       Date:  2013-12-05       Impact factor: 4.411

8.  ADAM15 mediates upregulation of Claudin-1 expression in breast cancer cells.

Authors:  Jens Mattern; Christian S Roghi; Melanie Hurtz; Vera Knäuper; Dylan R Edwards; Zaruhi Poghosyan
Journal:  Sci Rep       Date:  2019-08-29       Impact factor: 4.379

9.  ADAM-12 as a diagnostic marker for the proliferation, migration and invasion in patients with small cell lung cancer.

Authors:  Shuhong Shao; Zunling Li; Wei Gao; Guohua Yu; Dexiang Liu; Fang Pan
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

Review 10.  Influence of Immune Myeloid Cells on the Extracellular Matrix During Cancer Metastasis.

Authors:  David Jiang; Su Yin Lim
Journal:  Cancer Microenviron       Date:  2016-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.